Using genetically-engineered stem cells to create self-regulating treatments for arthritis
Genetically-engineered stem cells for self-regulating arthritis therapy
This study is exploring a new treatment for rheumatoid arthritis that uses specially designed stem cells to create implants that can automatically release anti-inflammatory medicine when your body needs it, making the treatment more personalized and potentially reducing side effects from regular medications.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11085264 on NIH RePORTER |
What this research studies
This research aims to develop a novel therapy for rheumatoid arthritis (RA) using genetically engineered stem cells that can sense inflammation levels in the body. By creating bioartificial implants, these stem cells will produce anti-inflammatory drugs in response to specific inflammatory signals, allowing for a more tailored treatment approach. This method seeks to reduce the adverse effects associated with traditional continuous drug administration by providing a self-regulating system that adjusts medication levels based on the patient's needs. Patients with RA may benefit from this innovative approach that combines synthetic biology and tissue engineering.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with rheumatoid arthritis or related inflammatory conditions.
Not a fit: Patients with non-inflammatory forms of arthritis or those who do not meet the age criteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with rheumatoid arthritis, minimizing side effects and improving quality of life.
How similar studies have performed: While the approach of using genetically engineered stem cells for self-regulating therapies is innovative, similar strategies in other areas of medicine have shown promise, indicating potential for success in this novel application.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Guilak, Farshid — Washington University
- Study coordinator: Guilak, Farshid
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.